BMS 188107
Latest Information Update: 18 Jan 2008
Price :
$50 *
At a glance
- Originator Bristol-Myers Squibb
- Class Anti-ischaemics; Ischaemic heart disorder therapies; Vasodilators
- Mechanism of Action Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Myocardial ischaemia
Most Recent Events
- 18 Jan 2005 Discontinued - Preclinical for Myocardial ischaemia in USA (unspecified route)
- 15 Mar 1995 Preclinical development for Myocardial ischaemia in USA (Unknown route)